Imagin Medical Inc C.IME

Alternate Symbol(s): IMEXF

Imagin Medical Inc. is a urologic oncology company. It is engaged in developing technologies to better visualize and treat urologic cancers through minimally invasive surgery, including bladder and prostate cancer. Its first product, enCAGE Coil, is designed to eliminate the limitations of other methods of prostate cancer treatment that can cause erectile dysfunction and urinary incontinence. The device is a disposable, focal therapy, precision ablation system that will deliver bipolar, radio frequency energy through a distinctive coil electrode, or cage. It enables the surgeon to preset margins for precise tissue targeting. Its second product, the i/Blue Imaging System, will bring several key technological advancements that improve the utility of blue light imaging for visualizing bladder cancer. The i/Blue System delivers blue light imaging technology in a more versatile, practical, and accessible format and is designed to work with existing fiberoptic endoscopes on the market.

CSE:IME - Post by User

Imagin Medical Inc

Bullboard Posts

Comment by NovaAU10000on Feb 12, 2018 6:08am

55 Views

Post# 27542997

RE:Imagin technology breakthrough.

NovaAU10000 wrote:

Imagin has developed extremely bright and high resolution optics they say are minimum 100X todays technology. They have also combined both screens into one image eliminating the doctors from having to switch back and forth during surgery. These two improvements alone are going to be significant for the doctors and patients. Reducing the image visualization time under 15min will be the icing on the cake. Imagin will be an attractive buy out candidate for several of the large bio-medical looking to update their own product offering.

One older analysis gave an estimated $3 to $4/sh valuation. With all three of Imagin's systems (i/Blue, i/Red, i/Vision) to consider, when fully functioning, that valuation may prove to be conservative.

ime will become the new standard of care.

Bullboard Posts

Silvercorp to expand into Ecuador with C$200M Adventus acquisition